Cancer research communications最新文献

{"title":"Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with Neuroblastoma.","authors":"Jan F Hollander, Annabell Szymansky, Jasmin Wünschel, Kathy Astrahantseff, Carolina Rosswog, Anne Thorwarth, Theresa M Thole-Kliesch, Rocío Chamorro González, Patrick Hundsdörfer, Kathrin Hauptmann, Karin Schmelz, Dennis Gürgen, Julian M M Rogasch, Anton G Henssen, Matthias Fischer, Johannes H Schulte, Cornelia Eckert, Angelika Eggert, Marco Lodrini, Hedwig E Deubzer","doi":"10.1158/2767-9764.CRC-24-0569","DOIUrl":"10.1158/2767-9764.CRC-24-0569","url":null,"abstract":"<p><strong>Significance: </strong>Real-time molecular monitoring of TERT-rearranged high-risk neuroblastoma is an unmet clinical need. We tested liquid biopsy-based assays for patient-individualized TERT breakpoint sequences to monitor disease in pediatric patients. Our digital PCR approach provides high resolution of spatial and temporal disease quantification in individual patients and is applicable for clinical routine.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":"167-177"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11774142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies.","authors":"Shivaani Kummar, Albiruni Abdul Razak, Scott Laurie, Dylan M Glatt, Sariah Kell, Anh N Diep, Maike Schmidt, Clifford Hom, Chris German, Suyash S Shringarpure, Sophia R Majeed, Drew Rasco","doi":"10.1158/2767-9764.CRC-24-0568","DOIUrl":"10.1158/2767-9764.CRC-24-0568","url":null,"abstract":"<p><strong>Purpose: </strong>In this phase 1 portion of a first-in-human phase 1/2a study (NCT05199272), 23ME-00610 was evaluated in participants with advanced solid malignancies to determine its safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD). Exploratory biomarkers were evaluated to examine potential correlates of efficacy and safety.</p><p><strong>Patients and methods: </strong>Eligible participants (≥18 years) were administered 23ME-00610 intravenously every 3 weeks (Q3W) using an accelerated titration design followed by a traditional 3 + 3 design, with an initial dose level of 2 mg.</p><p><strong>Results: </strong>Twenty-eight participants were enrolled across seven cohorts and received a median of four cycles of 23ME-00610. No treatment-related serious adverse events (AE) were observed, and the maximum tolerated dose was not reached. Overall, the PK of 23ME-00610 was linear and dose proportional for doses ≥60 mg, with a median terminal half-life of 13 days at 1,400 mg. Peripheral saturation of CD200R1 was observed for doses ≥60 mg. Immune-related AEs, including rash, pruritus, and hypothyroidism, were predicted by phenome-wide association studies and observed for doses ≥60 mg. A confirmed partial response was observed in a participant with well-differentiated pancreatic neuroendocrine cancer whose tumor was among those with the highest tumor CD200 expression.</p><p><strong>Conclusions: </strong>23ME-00610 has mild-to-moderate on-target AEs and PK/PD consistent with tumor target saturation and dosing every 3 weeks. The trend for clinical benefit in participants with tumor CD200 expression suggests that 23ME-00610 inhibits CD200R1 signaling and may reverse CD200-mediated immune evasion. Based on PK/PD, safety, and preliminary antitumor activity, 1,400 mg Q3W was selected as the dose for further study.</p><p><strong>Significance: </strong>Genome-wide association studies (GWAS) of the 23andMe genetic database identified CD200R1 as a promising therapeutic target for cancer. This phase 1 study of 23ME-00610, a CD200R1 antagonist IgG1, showed acceptable safety and tolerability, PK supporting Q3W dosing, and PD and preliminary clinical activity supporting an initial recommended phase 2 dose of 1,400 mg.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":"94-105"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11734590/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142803694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acknowledgment to Reviewers.","authors":"","doi":"10.1158/2767-9764.CRC-5-1-AR","DOIUrl":"https://doi.org/10.1158/2767-9764.CRC-5-1-AR","url":null,"abstract":"","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":"5 1","pages":"1-4"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Cost-Effective Two-Step Approach for Multi-Cancer Early Detection in High-Risk Populations.","authors":"Shuaipeng Geng, Shiyong Li, Wei Wu, Yinyin Chang, Mao Mao","doi":"10.1158/2767-9764.CRC-24-0508","DOIUrl":"10.1158/2767-9764.CRC-24-0508","url":null,"abstract":"<p><strong>Significance: </strong>Large-scale screening inevitably leads to significant financial burdens on the healthcare system, which is a key factor constraining nationwide screenings. The two-step MCED approach not only maintains comparable performance but also substantially alleviates financial strains compared with the direct use of next-generation sequencing-based MCED tests for massive screenings.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":"150-156"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11758400/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142911266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep Learning Predicts Subtype Heterogeneity and Outcomes in Luminal A Breast Cancer Using Routinely Stained Whole-Slide Images.","authors":"Nikhil Cherian Kurian, Peter H Gann, Neeraj Kumar, Stephanie M McGregor, Ruchika Verma, Amit Sethi","doi":"10.1158/2767-9764.CRC-24-0397","DOIUrl":"10.1158/2767-9764.CRC-24-0397","url":null,"abstract":"<p><strong>Significance: </strong>A deep learning model, trained using transcriptomic data, inexpensively quantifies and fine-maps ITH due to subtype admixture in routine images of LumA breast cancer, the most favorable subtype. This new approach could facilitate exploration of the mechanisms behind such heterogeneity and its impact on selection of therapy for individual patients.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":"157-166"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11770635/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142911229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting PRMT1 Reduces Cancer Persistence and Tumor Relapse in EGFR- and KRAS-Mutant Lung Cancer.","authors":"Xiaoxiao Sun, Karl Kumbier, Savitha Gayathri, Veronica Steri, Lani F Wu, Steven J Altschuler","doi":"10.1158/2767-9764.CRC-24-0389","DOIUrl":"10.1158/2767-9764.CRC-24-0389","url":null,"abstract":"<p><strong>Significance: </strong>Eliminating \"persisters\" before relapse is crucial for achieving durable treatment efficacy. This study provides a rationale for developing PRMT1-selective inhibitors to target cancer persisters and achieve more durable outcomes in oncogene-targeting therapies.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":"119-127"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11747858/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142856873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Ovarian Cancer Risk-Reducing Salpingectomy Acceptance: A Survey.","authors":"Alexandra Lukey, Ramlogan Sowamber, David Huntsman, Celeste Leigh Pearce, A Fuchsia Howard, Rafael Meza, Michael R Law, Minh Tung Phung, Gillian E Hanley","doi":"10.1158/2767-9764.CRC-24-0566","DOIUrl":"10.1158/2767-9764.CRC-24-0566","url":null,"abstract":"<p><strong>Significance: </strong>This study found that many participants were willing to consider RRS to prevent ovarian cancer. Further research on RRS should be undertaken to understand how this can be best used for ovarian cancer prevention.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":"187-194"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11780486/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142959789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer.","authors":"Shigehiro Koganemaru, Shohei Koyama, Fumitaka Suto, Makito Koga, Koichiro Inaki, Yusuke Kuwahara, Takeo Arita, Tsuyoshi Hirata, Hiroki Goto, Naoya Wada, Maki Kobayashi, Tomoko Shibutani, Tatsuya Okabayashi, Kenji Nakamaru, Akihito Kawazoe, Yousuke Togashi, Hiroyoshi Nishikawa, Kohei Shitara","doi":"10.1158/2767-9764.CRC-24-0302","DOIUrl":"10.1158/2767-9764.CRC-24-0302","url":null,"abstract":"<p><strong>Significance: </strong>This biomarker study explored HER2 expression levels and immune cell characteristics that may affect response to T-DXd using tumor tissue samples collected from clinical trial participants. The results suggest that HER2 expression levels and tumor characteristics before the initiation of T-DXd may correlate with the efficacy of the drug.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":"84-93"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11729160/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142831122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials.","authors":"Hailei Zhang, Anna Rutkowska, Antonio González-Martín, Mansoor R Mirza, Bradley J Monk, Ignace Vergote, Bhavana Pothuri, Whitney A Spannuth Graybill, Carsten Goessel, Olena Barbash, Giovanna Bergamini, Bin Feng","doi":"10.1158/2767-9764.CRC-24-0191","DOIUrl":"10.1158/2767-9764.CRC-24-0191","url":null,"abstract":"<p><strong>Significance: </strong>The presented retrospective analysis suggests, to the best of our knowledge for the first time, a potential significant interaction between statins and niraparib in clinical settings. Nevertheless, further investigations are required to gain a better understanding of the potential clinical benefit.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":"178-186"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775730/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142787863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies.","authors":"Georgia Mitsa, Livia Florianova, Josiane Lafleur, Adriana Aguilar-Mahecha, Rene P Zahedi, Sonia V Del Rincon, Mark Basik, Christoph H Borchers, Gerald Batist","doi":"10.1158/2767-9764.CRC-24-0287","DOIUrl":"10.1158/2767-9764.CRC-24-0287","url":null,"abstract":"<p><strong>Significance: </strong>This study provides real-world evidence for DCIS, a disease for which currently no molecular tools or biomarkers exist, and gives an unbiased, comprehensive, and deep proteomic profile, identifying >380 actionable targets.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":"138-149"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11755405/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142900801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}